Search
Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures – a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and staff.
A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering's new Brain Tumor Center (BTC).
After two studies examined the safety of eliminating axillary lymph node dissection (ALND) for some breast cancer patients, Memorial Sloan Kettering Cancer Center further tested their conclusions, confirmed the approach’s applicability and changed clinical practice.
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.
The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.
An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.
Researchers gain insight into leptomeningeal metastasis, a devastating complication of advanced cancer.
Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.
MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.